Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of DCR-PHXC in primary hyperoxaluria
MOH_2019-10-11_007442Phase 3Completed
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- May 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Long-term safety of DCR-PHXC. Started May 2019; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on MOH_2019-10-11_007442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-11_007442.